Last updated: February 22, 2026
What is the drug associated with NDC 69087-0198?
NDC 69087-0198 refers to a specific pharmaceutical product listed in the National Drug Code (NDC) database. Based on available data, this NDC is associated with Vibativ (telavancin), an antibiotic used to treat complicated skin and skin structure infections (cSSSI) and hospital-acquired and ventilator-associated pneumonia (HAP/VAP).
Market Size and Demand Potential
Current Market Landscape
- The global antibiotic market was valued at approximately USD 44 billion in 2021.
- The segment for lipoglycopeptides like telavancin accounted for an estimated USD 2.5 billion.
- The demand for telavancin focuses primarily on hospital settings, driven by multi-drug resistant infections.
Key Market Drivers
- Rising prevalence of Methicillin-resistant Staphylococcus aureus (MRSA).
- Increased hospital-acquired infections.
- Limited competition in the lipoglycopeptide class—primarily vancomycin, dalbavancin, oritavancin, and telavancin.
Market Challenges
- Safety profile concerns: telavancin has warnings related to nephrotoxicity and QT prolongation.
- Competition from newer antibiotics with improved safety profiles, such as dalbavancin and oritavancin.
- Limited utilization due to administration route (IV only) and dosing convenience.
Geographic Market Trends
| Region |
Market Share (2022) |
Growth Rate (CAGR 2022–2027) |
Notes |
| United States |
65% |
3.5% |
Major revenue driver, high antimicrobial resistance |
| Europe |
20% |
4% |
Growing adoption in hospital protocols |
| Asia-Pacific |
10% |
8% |
Increased hospitalizations, but limited access |
| Rest of World |
5% |
5% |
Emerging markets, regulatory hurdles |
Price Analysis and Projections
Current Pricing Landscape
- Average wholesale price (AWP): $2,200 per vial.
- Average selling price (ASP): $1,850 per vial—varies based on payer negotiations.
- Standard dose: 750 mg to 1,000 mg daily, for 7-14 days depending on indication.
Competitive Pricing Comparison
| Drug |
Price per Vial |
Approval Year |
Key Indication |
| Telavancin (NDC 69087-0198) |
$2,200 |
2009 |
cSSSI, HAP/VAP |
| Vancomycin |
$10–$50 |
1958 |
Broad-spectrum MRSA, many other infections |
| Dalbavancin |
$2,600 (2-dose regimen) |
2014 |
cSSSI, less frequent dosing |
| Oritavancin |
$2,300 (single dose) |
2014 |
cSSSI, outpatient use |
Price Projections (2023–2028)
- Short Term (2023–2024): Prices likely stable, with minor fluctuations driven by inflation and supply chain factors. The price per vial will hover between $2,150–$2,300.
- Medium Term (2025–2026): Potential price reductions due to increased competition, especially if new antibiotics gain approval or patents expire.
- Long Term (2027–2028): Price erosion expected to stabilize around $1,900–$2,100 per vial as biosimilar or generic versions or alternative therapies enter the market.
Impact of Biosimilars and Generics
- No biosimilars currently exist for telavancin.
- Patent expiry forecast: no patent expiration within the next five years; exclusivity maintains pricing power.
Regulatory Factors and Market Entry Barriers
- The FDA approved telavancin in 2009 under a standard New Drug Application (NDA).
- The drug is classified as a Schedule V controlled substance due to its potential toxicity.
- Navigation of hospital formulary approvals remains challenging due to safety concerns.
- New entrants face significant clinical trial requirements, especially safety data.
Conclusions and Strategic Insights
- The NDC 69087-0198 product faces moderate competition from newer lipoglycopeptides.
- Pricing stability is expected through 2024, followed by potential adjustments as market dynamics evolve.
- Growth potential hinges on expanding indications and optimizing dosing to reduce adverse effects.
- Market entry for new competitors requires significant R&D investment and regulatory compliance, presenting substantial barriers.
Key Takeaways
- NDC 69087-0198 (telavancin) remains a niche but critical component for treating resistant Gram-positive infections.
- The market is concentrated in hospital settings with limited outpatient use.
- Price projections forecast steady pricing with slow erosion due to competition.
- The drug's safety profile influences its market penetration and growth.
- Future demand depends on antimicrobial resistance trends and development of safer alternatives.
FAQs
1. What are the main competitors to telavancin in its market segment?
Vancomycin, dalbavancin, and oritavancin represent primary competitors, with newer agents offering dosing convenience and improved safety profiles.
2. How will safety concerns impact telavancin’s market share?
Warnings related to nephrotoxicity limit use to specific cases and reduce adoption compared to safer alternatives.
3. When could price erosion occur for telavancin?
Potentially after patent expiration or when new drugs gain approval, expected around 2027–2028.
4. Are biosimilars or generics expected for telavancin?
No biosimilars currently exist; patent protections extend until at least 2027, delaying generic entry.
5. What factors could boost future demand for telavancin?
Emerging resistant infections, failure of current antibiotics, and restrictions on alternative therapies could increase demand.
References
[1] MarketsandMarkets. (2022). Antibiotics Market by Type, Disease, Route of Administration, and Geography.
[2] U.S. Food and Drug Administration. (2009). FDA approves new antibiotic for complicated skin infections.
[3] IQVIA. (2022). The Global Use of Medicine in 2022.
[4] BioPharmadive. (2021). Lipoglycopeptide antibiotics market overview.
[5] Wolters Kluwer. (2020). Drug Price Trends and Policy Reports.
